Days gained response discriminates treatment response in patients with recurrent glioblastoma receiving bevacizumab-based therapies

BACKGROUND: Accurate assessments of patient response to therapy are a critical component of personalized medicine. In glioblastoma (GBM), the most aggressive form of brain cancer, tumor growth dynamics are heterogenous across patients, complicating assessment of treatment response. This study aimed...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neurooncol Adv
Päätekijät: Singleton, Kyle W, Porter, Alyx B, Hu, Leland S, Johnston, Sandra K, Bond, Kamila M, Rickertsen, Cassandra R, De Leon, Gustavo, Whitmire, Scott A, Clark-Swanson, Kamala R, Mrugala, Maciej M, Swanson, Kristin R
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Basic and Translational Investigations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7447137/
https://ncbi.nlm.nih.gov/pubmed/32864609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa085
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia